Skip to content
value.today

Macrolide Pharmaceuticals, Inc.

🇺🇸 Newton, Massachusetts, USAPharmaceuticalsFounded 2014
Total raised
$20 M
2 rounds on record
Latest round
$8 M
Apr 2020
First round on record
Feb 2015
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Macrolide Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2020$8 MNo. 2$2 to $10 million

Macrolide Pharmaceuticals, Inc.: Raise no. 2, Apr 2020

Investors in this round

4 investors had bought by the notice of Apr 16, 2020: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sumit Aggarwal · Executive Officer, Director
  • Christopher A. Viehbacher · Director
  • Raj B. Parekh, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Sumit Aggarwal, President, CEO, Treasurer and Secretary. Source: SEC Form D, newest notice filed Apr 16, 2020. Read the notice at the SEC.

equitySEC
Feb 2015$12 MNo. 1$10 to $50 million

Macrolide Pharmaceuticals, Inc.: Raise no. 1, Feb 2015

Investors in this round

10 investors had bought by the notice of Apr 29, 2016: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $28 M offered; $16 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew G. Littlehale · Executive Officer
  • Lawrence Miller · Executive Officer, Director
  • Andrew G. Myers · Director
  • Fereydoun G. Firouz · Director
  • Henry G. Skinner · Director
  • Monique G. Sciersing · Director
  • Raj G. Parekh · Director
  • Vikas G. Goyal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lawrence Miller, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Apr 29, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Macrolide Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2020).

    SEC Form D · Apr 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2020

That is all the official record says: Macrolide Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Macrolide Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Macrolide Pharmaceuticals, Inc.
NameRoleNamed in
Sumit AggarwalExecutive officerApr 2020
Andrew G. LittlehaleExecutive officerApr 2016
Lawrence MillerExecutive officerApr 2016
Christopher A. ViehbacherDirectorApr 2020
Raj B. Parekh, Ph.D.DirectorApr 2020
Sumit AggarwalDirectorApr 2020
Andrew G. MyersDirectorApr 2016
Fereydoun G. FirouzDirectorApr 2016
Henry G. SkinnerDirectorApr 2016
Lawrence MillerDirectorApr 2016
Monique G. SciersingDirectorApr 2016
Raj G. ParekhDirectorApr 2016
Vikas G. GoyalDirectorApr 2016